Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | OTHER_GOV |
| National Polytechnic Institute, Mexico | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to evaluate the effects of daily glycine supplementation on metabolic health and cognitive performance in older adults. Over a period of six months, participants received 1,000 mg of glycine per day to determine if this amino acid could improve markers of insulin resistance, glucose metabolism, and cognitive functions such as memory and executive tasks.
The research aimed to identify whether this nutritional intervention provides a safe and effective strategy to support healthy aging, focusing on the link between metabolic balance and brain health in the elderly population.
A 6-month longitudinal study was conducted, featuring a glycine supplementation phase followed by a dietary maintenance period. Cognitive assessments and serum BDNF levels were monitored at baseline, 3 months (T3), and 6 months (T6). Which included the evaluation of fasting glucose, insulin levels, insulin resistance indices, and specific metabolic biomarkers. Concurrently, cognitive functions were evaluated utilizing standardized neuropsychological instruments to measure changes in memory, attention, and executive function. Linear Mixed-Effects Models (LMM) were used to analyze temporal trajectories.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glycine group | Experimental | Participants received an oral daily dose of 1,000 mg of glycine for a duration of 6 months to evaluate metabolic and cognitive outcomes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glycine | Dietary Supplement | Oral supplementation of glycine at a dose of 1,000 mg per day, administered daily over a 6-month period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Brain-Derived Neurotrophic Factor (BDNF) levels | Serum concentrations of Brain-Derived Neurotrophic Factor (BDNF) measured via ELISA. Unit of Measure: pg/mL | Baseline (T0), 3 months (T3) and 6 months (T6) |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive performance evaluated by the Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). | Cognitive performance assessed using the Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). Total scores range from 0 to 30, where higher scores indicate better cognitive performance.
|
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive performance evaluated byMini-Mental State Examination (MMSE). | Cognitive performance assessed using the Mini-Mental State Examination (MMSE). Total scores range from o 27 - 30 points: Normal (No cognitive impairment).
|
Inclusion Criteria:
-Individuals across all nutritional statuses according to Body Mass Index (BMI): underweight, normal weight, overweight, and obesity.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brenda Sarahà BS Beristain Lujano, MSc | Escuela Superior de Medicina IPN | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Escuela Superior de Medicina | México | State of Mexico | 01710 | Mexico |
Individual participant data will not be shared to protect the privacy and confidentiality of the participants, in accordance with the informed consent and the guidelines of the Institutional Review Board (IRB).
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D060825 | Cognitive Dysfunction |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005998 | Glycine |
| ID | Term |
|---|---|
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Single-group, open-label study designed to evaluate longitudinal changes in metabolic and cognitive parameters from baseline (T0) to 6 months (T6) following daily glycine supplementation.
Not provided
Not provided
Not provided
Not provided
| Baseline (T0), 3 months (T3) and 6 months (T6) |
| Baseline (T0), 3 months (T3) and 6 months (T6) |
| D009750 |
| Nutritional and Metabolic Diseases |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |